Stock listing

NASDAQ:ARTL Artelo Biosciences, Inc. Stock

Home listing (NASDAQ) of Artelo Biosciences, Inc.

Follow Artelo Biosciences, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:ARTL

$1.39 USD -0.11 (-7.3%)

Close on Nov 20, 2026

Past year -97.0% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$1.31 – $1.49 USDNov 20, 2026
Volume
51,955 sharesNov 20, 2026
Market cap
$1.30M USDAt the close on Nov 20, 2026 · price × 937,177 shares outstanding
52-week range
$1.31 – $179.19 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$3.16M USDMedian day 41,000 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Artelo Biosciences, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:ARTL · Home$1.39 USD-0.11 (-7.3%)51,955$1.46$1.49$1.31$1.50Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:ARTL · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$1.39-0.11-7.3%$1.46$1.49$1.3151,955
$1.50-0.18-10.7%$1.71$1.71$1.4350,018
$1.68-0.02-1.2%$1.68$1.80$1.6521,035
$1.70-0.37-17.9%$2.05$2.055$1.61539,243
$2.07-0.03-1.4%$2.17$2.25$2.0513,852
$2.10-0.10-4.5%$2.205$2.25$2.0630,271
$2.20+0.058+2.7%$2.161$2.26$2.1426,528
$2.142+0.072+3.5%$2.13$2.42$2.1392,006
$2.07+0.16+8.4%$2.00$2.28$1.9346,449
$1.91-0.205-9.7%$2.05$2.226$1.9116,643
$2.115-0.155-6.8%$2.25$2.40$2.06152,795
$2.27-0.13-5.4%$2.42$2.42$2.208,469
$2.40+0.23+10.6%$2.14$2.405$2.1230,485
$2.17-0.05-2.3%$2.22$2.27$2.1245,031
$2.22-0.09-3.9%$2.25$2.285$2.1811,567
$2.31-0.02-0.9%$2.365$2.40$2.2553,434
$2.33+0.13+5.9%$2.24$2.42$2.2441,741
$2.200.000.0%$2.21$2.277$2.09530,470
$2.20-0.35-13.7%$2.54$2.54$2.15169,361
$2.550.000.0%$2.64$2.655$2.4826,100
$2.55-0.01-0.4%$2.62$2.64$2.5310,200
$2.56-0.06-2.3%$2.64$2.71$2.5617,400
$2.62-0.04-1.5%$2.698$2.80$2.6226,300
$2.66-0.04-1.5%$2.83$2.83$2.6616,300
$2.70-0.04-1.5%$2.75$2.759$2.7012,300
$2.74-0.14-4.9%$2.80$2.90$2.7417,600
$2.88-0.10-3.4%$2.95$2.97$2.8243,000
$2.98-0.13-4.2%$3.11$3.12$2.9230,800
$3.11-0.15-4.6%$3.172$3.25$3.1123,000
$3.26-0.11-3.3%$3.441$3.45$3.1945,500
$3.37-0.04-1.2%$3.51$3.51$3.3727,200
$3.41-0.05-1.4%$3.42$3.55$3.3349,900
$3.46-0.05-1.4%$3.65$3.74$3.4174,400
$3.51-0.17-4.6%$3.75$3.75$3.5046,900
$3.68-0.15-3.9%$3.85$3.85$3.6363,000
$3.83-0.21-5.2%$4.04$4.07$3.8092,400
$4.04-0.03-0.7%$4.06$4.30$3.9567,700
$4.07-0.23-5.3%$4.20$4.30$4.0587,000
$4.30-0.24-5.3%$4.44$4.55$4.25153,500
$4.54-0.63-12.2%$4.93$4.93$4.43256,500
$5.17-2.14-29.3%$4.87$5.35$4.511,050,400
$7.31+3.16+76.1%$4.03$15.73$3.9025,129,700
$4.15+0.05+1.2%$4.14$4.20$3.86324,300
$4.10+0.16+4.1%$3.89$4.19$3.88271,800
$3.94-0.03-0.8%$4.00$4.136$3.9229,400
$3.97+0.22+5.9%$3.84$4.02$3.69124,800
$3.75-1.59-29.8%$4.90$4.90$3.45276,600
$5.34+0.47+9.7%$4.88$5.65$4.8889,900
$4.87-0.56-10.3%$5.28$5.49$4.8654,800
$5.43-0.20-3.6%$5.69$5.84$5.3541,000
$5.63-0.35-5.9%$5.89$6.00$5.6141,300
$5.98-0.21-3.4%$6.415$6.415$5.9829,300
$6.19+0.15+2.5%$6.135$6.38$5.91810,700
$6.04-0.18-2.9%$6.25$6.345$5.9227,800
$6.22-0.30-4.6%$6.60$6.805$6.2227,700
$6.52+0.365+5.9%$6.10$6.706$5.99143,100
$6.155-0.205-3.2%$6.05$6.39$5.7084,300
$6.36+0.393+6.6%$5.95$6.79$5.34587,500
$5.967+0.018+0.3%$5.931$6.12$5.56229,635
$5.949-0.45-7.0%$6.102$6.282$4.6810,289
$6.399-0.054-0.8%$6.345$6.57$6.3451,142
$6.453+0.252+4.1%$6.30$6.462$6.121,751
$6.201-0.027-0.4%$6.111$6.39$5.941,268
$6.228-0.18-2.8%$6.48$6.57$6.121,343
$6.408-0.072-1.1%$6.444$6.75$6.304,330

Splits

4 splits since 2022 · NASDAQ:ARTL · every price before a split is adjusted for it

DayRatioWhat
1-for-9Consolidation
1-for-3Consolidation
1-for-6Consolidation
1-for-15Consolidation
Ticker
NASDAQ:ARTL
Asset type
Stock
Sector
Health care
Industry
Biotechnology
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Artelo Biosciences, Inc. news

Artelo Biosciences, Inc. on 6ix

Sector
Health care
Industry
Biotechnology
News releases
26 in the last 12 months · 115 in all · newest Nov 12, 2026 · oldest 2019
Decks
7 decks · latest September 2026

Where Artelo Biosciences, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:ARTL · Home listing · This pageNASDAQUnited StatesUSD
BOATS:ARTLBOATSUnited StatesUSD

Cash and shares

Aug 31, 2026 · Artelo Biosciences — Investor Presentation (September 2026)

Shares outstanding
540,667

The slide these figures come from

Valuation

Price/book 0.2× against a median of 0.3×: 3rd lowest of 8 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
$1.34M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.2×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.36

Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Artelo Biosciences, Inc. · NASDAQ:ARTLUS$1.30MUS$1.34Mn/an/an/a0.2×n/a0.0×1.36
Jupiter Neurosciences, Inc. · NASDAQ:JUNSUS$1.63MUS$1.33Mn/a16.9×n/an/an/an/a1.88
Kairos Pharma, Ltd. · AMEX:KAPAUS$1.48M−US$1.65Mn/an/an/a0.4×n/a0.0×1.36
BioRestorative Therapies, Inc. · NASDAQ:BRTXUS$1.45M−US$2.11Mn/a−5.9×n/a0.5×n/a0.0×1.81
Nutra Pharma Corp. · OTC:NPHCUS$1.43MUS$13.99Mn/a87.0×n/an/an/an/an/a
Aptevo Therapeutics Inc. · NASDAQ:APVOUS$1.40M−US$2.88Mn/an/an/a0.4×n/a1.0×0.93
Agentix Corp. · OTC:AGTXUS$1.35MUS$1.34Mn/an/an/an/an/an/a-0.73
Clearmind Medicine Inc. · NASDAQ:CMNDUS$1.33M−US$9.01Mn/an/an/a0.2×n/a0.0×0.29
International Stem Cell Corporation · OTC:ISCOUS$1.28M−US$18.76M0.1×−2.0×n/a0.1×222.6%0.0×-0.52
SureNano Science Ltd · CSE:SUREUS$1.17MUS$672,321n/an/an/a0.3×n/a0.0×0.25
Valion Bio, Inc. · NASDAQ:VBIOUS$1.04MUS$16.34Mn/a42.8×n/a0.2×n/a4.1×1.11
Median of the othersUS$1.37M−US$488,4960.1×16.9×0.3×222.6%0.0×0.93

Forecasts

Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.

Price target
18.00 USD · Analysts' mean
EPS, year to Dec 2026
-9.84 · 1 analyst

Team and board

Officers

OfficerRole
Gregory GorgasPresident & Chief Executive Officer
Mark SpringChief Financial Officer
Andy YatesSenior Vice President, Chief Scientific Officer
Jason BaybuttSenior Vice President, Finance
Saoirse Elizabeth O’SullivanVice President, Translational Sciences
Steven D. ReichChief Medical Officer

Board

DirectorRole
Connie MatsuiChair
Douglas BlayneyBoard Member
Greg ReyesBoard Member
Gregory GorgasPresident & Chief Executive Officer
Martin EmanueleBoard Member
Steven KellyBoard Member
Tamara A. FavoritoBoard Member

Events

QuarterResultsShare move
Q3 2026Nov 12, 2026−5.9%
Q2 2026Aug 12, 2026+1.9%
Q1 2026May 15, 2026−37.6%
Q4 2025Feb 24, 2026 · Before open+4.8%
Q3 2025Nov 12, 2025 · Before open−8.2%
Q2 2025Aug 13, 2025 · Before open+4.2%
Q1 2025May 13, 2025 · Before open+3.0%
Q4 2024Mar 24, 2025 · Before open−5.7%
Q3 2024Nov 12, 2024 · Before open−5.4%
Q2 2024Aug 13, 2024 · Before open+2.8%
All 20 quarters
QuarterResultsShare move
Q1 2024May 13, 2024 · Before open−3.0%
Q4 2023Mar 25, 2024 · Before open−0.9%
Q3 2023Nov 13, 2023 · Before open0.0%
Q2 2023Aug 10, 2023 · Before open0.0%
Q1 2023May 11, 2023 · Before open−1.4%
Q4 2022Mar 31, 2023+15.6%
Q3 2022Nov 8, 2022 · Before open+4.7%
Q2 2022Aug 9, 2022 · Before open−23.7%
Q1 2022May 12, 2022 · Before open+7.8%
Q4 2021Jan 12, 2022 · Before open+0.8%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (September 2026)Investor deck25 slidesSeptember 2026
Investor Presentation (November 2019)Investor deck27 slidesNov 15, 2019
Investor Presentation (June 2019)Investor deck27 slidesJune 2019
Investor Presentation (January 2019)Investor deck24 slidesJanuary 2019
Investor Presentation (May 2018)Investor deck28 slidesMay 30, 2018
Investor Presentation (March 2018)Investor deck28 slidesMarch 2018
Investor Presentation (May 2017)Investor deck24 slidesMay 16, 2017

Open Decks

Financings

RaiseDate
Public offering of common stock and pre-funded warrants
Closed: US$2M raised · US$4.4 a share · R.F. Lafferty & Co., Inc.
Dealers: R.F. Lafferty & Co., Inc. (lead)
Oct 1, 2025
Public offering of shares of common stock and pre-funded warrants
Closed: US$3M raised · US$4.4 a share · R. F. Lafferty & Co., Inc.
Dealers: R. F. Lafferty & Co., Inc. (lead)
Sep 5, 2025
Private placement of shares of common stock (or pre-funded warrants) and warrants
Announced: about US$9.47M · US$10.45 a share · three-year warrants to purchase 906,687 shares at $10.20 per share and three-year… · R. F. Lafferty & Co., Inc.
Dealers: R. F. Lafferty & Co., Inc.
Buyers: Bartosz Lipiński (lead investor)
Use of proceeds: Launch a Solana (SOL)-centric digital asset treasury strategy and support ongoing business
Aug 4, 2025
Private placement of shares of common stock, pre-funded warrants and accompanying warrants
Announced: about US$1.43M · accompanying warrants to purchase 460,046 shares at $5.82 per share and 230,023 shares…
Use of proceeds: Announce clinical data for ART26.12 and ART27.13 studies; $250,000 to buy SOL digital currency; balance for general corporate and working capital
Jun 26, 2025
At-market convertible notes
Closed: US$900,000 raised
Use of proceeds: To fund company operations until additional financing is completed
May 13, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Declared effective by the SEC on Jan 28, 2015. Filed with the SEC to go public on Oct 8, 2014, as KNIGHT KNOX DEVELOPMENT CORP.

Shares offered
8,000,000 shares of common stock

Steps

StepWhen
Filed publiclyOct 8, 2014
Amended twiceNewest Jan 23, 2015
Declared effective by the SECJan 28, 2015
Shares registered with an exchangeJun 21, 2019
Final prospectus, with the priceNot yet

Filings

FilingFiled
CORRESP · Letter to the SECMay 15, 2026
UPLOAD · Letter from the SECMay 11, 2026
CORRESP · Letter to the SECApr 13, 2026
UPLOAD · Letter from the SECApr 13, 2026
CORRESP · Letter to the SECMar 25, 2026
CORRESP · Letter to the SECMar 20, 2026
CORRESP · Letter to the SECMar 20, 2026
UPLOAD · Letter from the SECMar 13, 2026
CORRESP · Letter to the SECDec 1, 2025
CORRESP · Letter to the SECJul 16, 2025
All 48 filings
FilingFiled
UPLOAD · Letter from the SECJul 16, 2025
CORRESP · Letter to the SECJul 12, 2023
UPLOAD · Letter from the SECJul 10, 2023
CORRESP · Letter to the SECMay 26, 2022
UPLOAD · Letter from the SECMay 26, 2022
S-1MEF · Registration of more shares for the same offeringOct 9, 2020
CORRESP · Letter to the SECOct 7, 2020
CORRESP · Letter to the SECOct 7, 2020
UPLOAD · Letter from the SECOct 2, 2020
UPLOAD · Letter from the SECApr 22, 2020
CORRESP · Letter to the SECApr 21, 2020
UPLOAD · Letter from the SECApr 7, 2020
CORRESP · Letter to the SECMar 27, 2020
UPLOAD · Letter from the SECMar 23, 2020
CORRESP · Letter to the SECFeb 3, 2020
UPLOAD · Letter from the SECJan 21, 2020
CORRESP · Letter to the SECDec 19, 2019
CORRESP · Letter to the SECDec 19, 2019
CORRESP · Letter to the SECNov 12, 2019
CORRESP · Letter to the SECNov 8, 2019
UPLOAD · Letter from the SECNov 8, 2019
UPLOAD · Letter from the SECJul 31, 2019
CERT · Exchange's certificate of listingJun 21, 2019
8-A12B · Registration of shares for listing on an exchangeJun 21, 2019
CORRESP · Letter to the SECJun 20, 2019
CORRESP · Letter to the SECJun 20, 2019
UPLOAD · Letter from the SECOct 4, 2018
CORRESP · Letter to the SECOct 3, 2018
CORRESP · Letter to the SECMay 25, 2018
UPLOAD · Letter from the SECMay 1, 2018
UPLOAD · Letter from the SECMar 27, 2018
UPLOAD · Letter from the SECFeb 27, 2018
EFFECT · Notice that a registration is effectiveJan 28, 2015
CORRESP · Letter to the SECJan 23, 2015
S-1/A · Registration statement, amendedJan 23, 2015
S-1/A · Registration statement, amendedDec 24, 2014
UPLOAD · Letter from the SECNov 3, 2014
S-1 · Registration statementOct 8, 2014

Open IPO · From the cover of the amended prospectus (S-1/A) filed Jan 23, 2015

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2021FY2020FY2020FY2019FY2019
Revenue0000000
Research and development5.42M5.99M5.70M4.32M3.78M2.84M1.92M1.92M1.09M1.09M
Selling, general and administrative5.98M4.12M4.23M5.96M4.60M2.77M2.12M
Operating income-11.4M-10.1M-9.93M-10.3M-9.42M-7.44M-4.69M-4.69M-3.21M-3.21M
Depreciation and amortization146.0K2.00K311500500510510
EBITDA-11.3M-10.3M-9.42M-4.69M-4.69M-3.21M-3.21M
Interest expense194.0K005.00K0000
Income before tax-12.9M-9.83M-9.29M-10.1M-7.44M-4.66M-2.17M
Income tax000000-60.4K0-2.04M0
Net income-12.9M-9.83M-9.29M-10.1M-9.41M-7.44M-4.66M-4.66M-2.17M-2.17M
Earnings per share, basic-172.23-17.31-2.91-3.53-3.34-0.40-338.99-1.26-269.97-1.00
Earnings per share, diluted-12.52-18.30-3.14-0.40-1.26-1.46

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2021FY2020FY2020FY2019FY2019
Cash and equivalents600.0K2.34M2.81M6.89M12.2M6.63M2.14M2.14M4.42M4.42M
Short-term investments07.61M9.15M12.0M3.44M001.50K
Receivables8.79K
Inventory-8.79K
Current assets695.0K2.56M11.0M18.3M24.6M10.3M2.34M2.34M4.44M4.44M
Property, plant and equipment90.0K246246721721
Total assets2.80M4.70M13.0M20.4M28.3M12.6M4.38M4.38M6.48M6.48M
Accounts payable3.04M1.68M1.24M905.0K471.0K489.0K348.9K639.4K
Current liabilities4.04M1.77M1.29M998.0K1.03M526.0K501.0K501.0K1.02M1.02M
Total debt678.0K104.0K23.0K63.0K95.0K
Total liabilities4.07M1.84M1.29M1.02M1.08M593.0K501.0K501.0K1.02M
Shareholders' equity-1.27M2.86M11.8M19.4M27.2M12.0M3.88M3.88M5.46M5.46M
Shares outstanding74.8K567.6K3.19M2.86M2.82M1.64M13.7K4.99M8.05K3.35M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2021FY2020FY2020FY2019FY2019
Cash from operations-8.52M-8.35M-8.21M-8.01M-6.14M-6.14M-4.35M-4.35M-2.79M-2.79M
Capital spending00000-1.50M-1.50M
Free cash flow-8.52M-8.35M-8.21M-8.01M-6.14M-4.35M-4.29M
Cash from investing-62.0K7.77M3.51M2.96M-3.44M-3.44M-3.44M0-1.50M-1.50M
Cash from financing6.87M112.0K567.0K014.1M14.1M1.98M1.98M8.38M8.38M
Share buybacks9-1088.38M
Change in cash-1.74M-477.0K-4.07M-5.27M4.49M4.49M-2.28M-2.28M4.09M4.09M

Open Financials

Filings

FilingDateTypeFiled with
10-Q · Quarterly reportNov 12, 2026Quarterly reportSEC
8-K · Current reportOct 9, 2026Current reportSEC
8-K · Current reportAug 27, 2026Current reportSEC
10-Q/A · Quarterly report, amendedAug 20, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 13, 2026Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2026Quarterly reportSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
4 · Change in ownershipJul 21, 2026Insider tradeSEC
8-K · Current reportJul 17, 2026Meeting outcomeSEC
DEFA14A · Additional proxy materialJul 16, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialJul 15, 2026Meeting noticeSEC
DEFA14A · Additional proxy materialJul 2, 2026Meeting noticeSEC
PRER14AJun 22, 2026Other filingsSEC
ARS · Annual report to shareholdersJun 5, 2026Annual reportSEC
DEFA14A · Additional proxy materialJun 5, 2026Meeting noticeSEC
DEF 14A · Proxy statementJun 5, 2026Meeting noticeSEC
8-K · Current reportMay 27, 2026Material contractSEC
PRE 14A · Preliminary proxy statementMay 26, 2026Meeting noticeSEC
424B5 · ProspectusMay 26, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveMay 20, 2026Other filingsSEC
424B5 · ProspectusMay 18, 2026Offer documentSEC
CORRESP · Letter to the SECMay 15, 2026Other filingsSEC
8-K · Current reportMay 15, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeMay 15, 2026Big-stake noticeSEC
10-Q · Quarterly reportMay 14, 2026Quarterly reportSEC
S-3/A · Registration statement, amendedMay 14, 2026Offer documentSEC
UPLOAD · Letter from the SECMay 11, 2026Other filingsSEC
S-3 · Registration statementMay 4, 2026Offer documentSEC
424B3 · ProspectusApr 16, 2026Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 16, 2026Other filingsSEC
CORRESP · Letter to the SECApr 13, 2026Other filingsSEC
UPLOAD · Letter from the SECApr 13, 2026Other filingsSEC
S-1 · Registration statementApr 7, 2026Offer documentSEC
8-K · Current reportApr 7, 2026Current reportSEC
DApr 6, 2026Other filingsSEC
SCHEDULE 13G · Big-stake noticeApr 3, 2026Big-stake noticeSEC
EFFECT · Notice that a registration is effectiveMar 31, 2026Other filingsSEC
8-K · Current reportMar 30, 2026Material contractSEC
DMar 27, 2026Other filingsSEC
DMar 27, 2026Other filingsSEC
DMar 27, 2026Other filingsSEC
RW · Request to withdraw a registrationMar 27, 2026Other filingsSEC
8-K · Current reportMar 26, 2026Material contractSEC
EFFECT · Notice that a registration is effectiveMar 26, 2026Other filingsSEC
CORRESP · Letter to the SECMar 25, 2026Other filingsSEC
S-1 · Registration statementMar 24, 2026Offer documentSEC
S-1/A · Registration statement, amendedMar 24, 2026Offer documentSEC
S-1/A · Registration statement, amendedMar 23, 2026Offer documentSEC
CORRESP · Letter to the SECMar 20, 2026Other filingsSEC
CORRESP · Letter to the SECMar 20, 2026Other filingsSEC
S-1 · Registration statementMar 20, 2026Offer documentSEC
8-K · Current reportMar 18, 2026Material contractSEC
8-K · Current reportMar 17, 2026ResultsSEC
UPLOAD · Letter from the SECMar 13, 2026Other filingsSEC
DRS · Draft registration statementMar 9, 2026Offer documentSEC
8-K · Current reportMar 6, 2026Current reportSEC
10-K · Annual reportFeb 24, 2026Annual reportSEC
DFeb 5, 2026Other filingsSEC
8-K · Current reportFeb 5, 2026Material contractSEC
8-K · Current reportFeb 5, 2026Current reportSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
4 · Change in ownershipFeb 2, 2026Insider tradeSEC
8-K · Current reportJan 30, 2026Meeting outcomeSEC
8-K · Current reportJan 16, 2026Current reportSEC
DEFA14A · Additional proxy materialJan 7, 2026Meeting noticeSEC
8-K · Current reportJan 2, 2026Current reportSEC
ARS · Annual report to shareholdersDec 11, 2025Annual reportSEC
DEF 14A · Proxy statementDec 11, 2025Meeting noticeSEC
EFFECT · Notice that a registration is effectiveDec 3, 2025Other filingsSEC
CORRESP · Letter to the SECDec 1, 2025Other filingsSEC
8-K · Current reportNov 25, 2025Current reportSEC
3 · Initial statement of ownershipNov 17, 2025Insider tradeSEC
S-1 · Registration statementNov 17, 2025Offer documentSEC
8-K · Current reportNov 14, 2025Current reportSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
DNov 10, 2025Other filingsSEC
8-K · Current reportOct 31, 2025Material contractSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
4 · Change in ownershipOct 30, 2025Insider tradeSEC
8-K · Current reportOct 27, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 21, 2025Big-stake noticeSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 17, 2025Big-stake noticeSEC
8-K · Current reportOct 17, 2025Material contractSEC
SCHEDULE 13D/A · Big-stake notice, amendedOct 3, 2025Big-stake noticeSEC
8-K · Current reportOct 1, 2025Material contractSEC
424B5 · ProspectusOct 1, 2025Offer documentSEC
424B5 · ProspectusSep 30, 2025Offer documentSEC
424B5 · ProspectusSep 30, 2025Offer documentSEC
DRS · Draft registration statementSep 29, 2025Offer documentSEC
SCHEDULE 13D · Big-stake noticeSep 19, 2025Big-stake noticeSEC
8-K · Current reportSep 15, 2025Current reportSEC
8-K · Current reportSep 10, 2025Current reportSEC
8-K · Current reportSep 5, 2025Material contractSEC
424B5 · ProspectusSep 5, 2025Offer documentSEC
424B5 · ProspectusSep 4, 2025Offer documentSEC
424B5 · ProspectusSep 4, 2025Offer documentSEC
8-K · Current reportSep 3, 2025Current reportSEC
8-K · Current reportAug 29, 2025Meeting outcomeSEC
8-K · Current reportAug 20, 2025Current reportSEC
DAug 13, 2025Other filingsSEC
10-Q · Quarterly reportAug 13, 2025Quarterly reportSEC
DEF 14A · Proxy statementAug 7, 2025Meeting noticeSEC
8-K · Current reportAug 7, 2025Material contractSEC
8-K · Current reportAug 4, 2025Material contractSEC
PRE 14A · Preliminary proxy statementJul 28, 2025Meeting noticeSEC
8-K · Current reportJul 18, 2025Material contractSEC
424B5 · ProspectusJul 18, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveJul 18, 2025Other filingsSEC
CORRESP · Letter to the SECJul 16, 2025Other filingsSEC
UPLOAD · Letter from the SECJul 16, 2025Other filingsSEC
S-1 · Registration statementJul 11, 2025Offer documentSEC
8-K · Current reportJul 11, 2025ResultsSEC
DJul 9, 2025Other filingsSEC
4 · Change in ownershipJul 7, 2025Insider tradeSEC
8-K · Current reportJun 26, 2025Material contractSEC
8-K · Current reportJun 13, 2025Current reportSEC
8-K · Current reportMay 23, 2025Current reportSEC
10-Q · Quarterly reportMay 13, 2025Quarterly reportSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
4 · Change in ownershipMay 5, 2025Insider tradeSEC
8-K · Current reportMay 1, 2025Material contractSEC
8-K · Current reportApr 29, 2025Current reportSEC
S-8 · Registration statement for employee plansMar 20, 2025Offer documentSEC
10-K · Annual reportMar 3, 2025Annual reportSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
4 · Change in ownershipDec 23, 2024Insider tradeSEC
8-K · Current reportDec 20, 2024Meeting outcomeSEC
10-Q · Quarterly reportNov 12, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialNov 8, 2024Meeting noticeSEC
DEF 14A · Proxy statementNov 8, 2024Meeting noticeSEC
ARS · Annual report to shareholdersNov 8, 2024Annual reportSEC
10-Q · Quarterly reportAug 13, 2024Quarterly reportSEC
25-NSEJun 17, 2024Other filingsSEC
10-Q · Quarterly reportMay 13, 2024Quarterly reportSEC
S-8 · Registration statement for employee plansMar 28, 2024Offer documentSEC
10-K · Annual reportMar 25, 2024Annual reportSEC
8-K · Current reportMar 4, 2024Management or board changeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipMar 1, 2024Insider tradeSEC
4 · Change in ownershipJan 8, 2024Insider tradeSEC
10-Q · Quarterly reportNov 13, 2023Quarterly reportSEC
10-Q · Quarterly reportAug 10, 2023Quarterly reportSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
4 · Change in ownershipAug 8, 2023Insider tradeSEC
8-K · Current reportAug 8, 2023Management or board changeSEC
EFFECT · Notice that a registration is effectiveJul 17, 2023Other filingsSEC
CORRESP · Letter to the SECJul 12, 2023Other filingsSEC
UPLOAD · Letter from the SECJul 10, 2023Other filingsSEC
DEL AMJul 7, 2023Other filingsSEC
S-3 · Registration statementJul 6, 2023Offer documentSEC
8-K · Current reportJul 3, 2023Meeting outcomeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
4 · Change in ownershipJul 3, 2023Insider tradeSEC
DEFA14A · Additional proxy materialMay 16, 2023Meeting noticeSEC
DEF 14A · Proxy statementMay 16, 2023Meeting noticeSEC
ARS · Annual report to shareholdersMay 16, 2023Annual reportSEC
10-Q · Quarterly reportMay 11, 2023Quarterly reportSEC
PRE 14A · Preliminary proxy statementMay 5, 2023Meeting noticeSEC
S-8 · Registration statement for employee plansApr 21, 2023Offer documentSEC
8-K · Current reportApr 21, 2023Current reportSEC
10-K · Annual reportMar 31, 2023Annual reportSEC
8-K · Current reportMar 13, 2023Current reportSEC
4 · Change in ownershipFeb 1, 2023Insider tradeSEC
10-Q · Quarterly reportNov 8, 2022Quarterly reportSEC
8-K · Current reportSep 16, 2022Meeting outcomeSEC
8-K · Current reportAug 25, 2022Current reportSEC
4 · Change in ownershipAug 12, 2022Insider tradeSEC
4 · Change in ownershipAug 11, 2022Insider tradeSEC
8-K · Current reportAug 9, 2022Current reportSEC
10-Q · Quarterly reportAug 9, 2022Quarterly reportSEC

This page holds 200 of 466 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Artelo Biosciences, Inc.’s releases · as of Nov 11, 2026

Common shares
937,177
Fully diluted
937,177

Fully diluted

LineSharesAs of
Common shares937,177Nov 11, 2026

Share count over time

CountShares
Nov 11, 2026937,177

Open Cap table

Shareholders

HolderSharesOf the companyValueAs of
Vanguard Extended Market Index Fund10,1291.1%US$11,344Jun 30, 2026
Fidelity Extended Market Index Fund6,3760.68%US$8,926May 31, 2026
Fidelity Series Total Market Index Fund2330.02%US$326May 31, 2026
Fidelity Nasdaq Composite Index Fund1810.02%US$253May 31, 2026

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Connie Matsui
Other companies: Sutro Biopharma, Inc. (Director · Since at least Jun 24, 2019); Halozyme Therapeutics, Inc. (Director · May 15, 2007 – Nov 29, 2024 · Past)
Chair · Since at least Jun 21, 2019
Gregory Gorgas
Other companies: Savara, Inc. (Senior VP, Commercial · Jul 21, 2011 – Jan 4, 2016 · Past)
President & Chief Executive Officer · Since at least Jun 21, 2019
Gregory Reyes
Other companies: Bio Green Med Solution, Inc. (Senior VP, Research · Jun 22, 2007 – Dec 22, 2007 · Past)
Director · Since at least Nov 30, 2020
John W Beck
Other companies: AIxCrypto Holdings, Inc. (Chief Financial Officer · May 18, 2020 – May 18, 2020 · Past)
Director · Dec 6, 2019 – Jul 16, 2021 · Past
Steven Kelly
Other companies: Carisma Therapeutics, Inc. (President and CEO, Director · Mar 7, 2023 – Jan 28, 2025 · Past)
Director · Since at least Jun 21, 2019
Andy YatesSenior Vice President, Chief Scientific Officer · Since at least Sep 29, 2025
Douglas BlayneyBoard Member · Since at least Jun 21, 2019
Greg ReyesBoard Member · Since at least Nov 4, 2026
Jason BaybuttSenior Vice President, Finance · Since at least Nov 5, 2026
Mark SpringChief Financial Officer · Since at least Oct 27, 2025
All 16 people
PersonSeat
Martin EmanueleBoard Member · Since at least Nov 5, 2026
Robert Martin EmanueleDirector · Since at least Jan 30, 2026
Saoirse Elizabeth O’SullivanVice President, Translational Sciences · Since at least Oct 29, 2026
Steven D. ReichChief Medical Officer · Since at least Sep 29, 2025
Steven KellyBoard Member · Since at least Nov 4, 2026
Tamara A. FavoritoBoard Member · Since at least Nov 5, 2026

Open People

Log in to ask 6ix AI your own questions about Artelo Biosciences, Inc.